Paper35628443
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
Feijóo-Bandín S and 10 others. Int J Mol Sci, 2022. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Papers, record 35628443. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35628443
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Heart Failure | Major topic |
| Sodium-Glucose Transporter 2 Inhibitors | Major topic |
| Animals | |
| Glucose | |
| Humans | |
| Inflammation | |
| Models, Animal | |
| Sodium | |
| Sodium-Glucose Transporter 2 |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PI21/01145 | Instituto de Salud Carlos III | PubMed | ||
| Project number 734899 | European Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 Programme | PubMed | ||
| GPC IN607B 2021 108 | Axencia Galega de Innovacion | PubMed |
Source PubMed
References220
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32585073 | Role of NLRP3 inflammasome in liver disease. | J Dig Dis | 2020 | https://conductscience.org/library/papers/32585073 | PubMed |
| 2 | 33611885 | Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. | Diabetes Metab J | 2021 | https://conductscience.org/library/papers/33611885 | PubMed |
| 3 | 16307390 | Prevention of bone loss by phloridzin, an apple polyphenol, in ovariectomized rats under inflammation conditions. | Calcif Tissue Int | 2005 | https://conductscience.org/library/papers/16307390 | PubMed |
| 4 | 24848755 | Tofogliflozin: first global approval. | Drugs | 2014 | https://conductscience.org/library/papers/24848755 | PubMed |
| 5 | 15624123 | Phlorizin: a review. | Diabetes Metab Res Rev | 2005 | https://conductscience.org/library/papers/15624123 | PubMed |
| 6 | 28045402 | Inflammatory mechanisms linking obesity and metabolic disease. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28045402 | PubMed |
| 7 | 3571496 | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. | J Clin Invest | 1987 | https://conductscience.org/library/papers/3571496 | PubMed |
| 8 | 33760995 | Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy. | Acta Diabetol | 2021 | https://conductscience.org/library/papers/33760995 | PubMed |
| 9 | 33005037 | Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. | Nat Rev Nephrol | 2021 | https://conductscience.org/library/papers/33005037 | PubMed |
| 10 | 34002329 | Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis. | Inflammopharmacology | 2021 | https://conductscience.org/library/papers/34002329 | PubMed |
| 11 | 31896553 | Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. | Diabetes | 2020 | https://conductscience.org/library/papers/31896553 | PubMed |
| 12 | 20302302 | (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. | J Med Chem | 2010 | https://conductscience.org/library/papers/20302302 | PubMed |
| 13 | 17167474 | Inflammation and metabolic disorders. | Nature | 2006 | https://conductscience.org/library/papers/17167474 | PubMed |
| 14 | 23776070 | Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures. | Mol Nutr Food Res | 2013 | https://conductscience.org/library/papers/23776070 | PubMed |
| 15 | 17050778 | Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. | J Pharmacol Exp Ther | 2007 | https://conductscience.org/library/papers/17050778 | PubMed |
| 16 | 16306358 | Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. | Diabetes | 2005 | https://conductscience.org/library/papers/16306358 | PubMed |
| 17 | 29512713 | Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. | Mol Med Rep | 2018 | https://conductscience.org/library/papers/29512713 | PubMed |
| 18 | 33115828 | Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench. | Diabetes | 2021 | https://conductscience.org/library/papers/33115828 | PubMed |
| 19 | 10036327 | Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. | Biochim Biophys Acta | 1999 | https://conductscience.org/library/papers/10036327 | PubMed |
| 20 | 35418866 | Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35418866 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42236640 | Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study. | Infect Dis Ther | 2026 | https://conductscience.org/library/papers/42236640 | PubMed |
| 42232589 | Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42232589 | PubMed |
| 42195246 | Uncoupling Erythropoiesis from Cardiorenal Effects: SGLT2 Inhibition in Non-Diabetic Heart Failure. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42195246 | PubMed |
| 41899183 | SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899183 | PubMed |
| 41545323 | Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/41545323 | PubMed |
| 41499173 | Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of IFN Genes Pathway in Renal Tubular Epithelial Cells. | Kidney360 | 2026 | https://conductscience.org/library/papers/41499173 | PubMed |
| 41466578 | Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. | Arthritis Rheumatol | 2026 | https://conductscience.org/library/papers/41466578 | PubMed |
| 41011188 | Modulation of Macrophage Polarization by Traditional Chinese Medicine in HFpEF: A Review of Mechanisms and Therapeutic Potentials. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41011188 | PubMed |
| 41010553 | Beyond the Cardio-Renal-Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins. | J Clin Med | 2025 | https://conductscience.org/library/papers/41010553 | PubMed |
| 40420176 | Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. | Cardiovasc Diabetol | 2025 | https://conductscience.org/library/papers/40420176 | PubMed |
| 40193211 | Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies. | J Am Soc Nephrol | 2025 | https://conductscience.org/library/papers/40193211 | PubMed |
| 40182430 | Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40182430 | PubMed |
| 40149704 | Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149704 | PubMed |
| 40004134 | Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004134 | PubMed |
| 39639415 | Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors. | Kidney Res Clin Pract | 2025 | https://conductscience.org/library/papers/39639415 | PubMed |
| 39254877 | The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/39254877 | PubMed |
| 39211720 | A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects. | Cureus | 2024 | https://conductscience.org/library/papers/39211720 | PubMed |
| 39062954 | The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39062954 | PubMed |
| 38791409 | The Role of Inflammasomes in Heart Failure. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791409 | PubMed |
| 38675438 | View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38675438 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35628443
GET https://conductscience.org/api/papers/v1/35628443/references?page=2